Contact Us

Antitope Ltd
Babraham Research Campus
Babraham
Cambridge CB22 3AT
United Kingdom

Telephone: +44(0) 1223 496190
Fax: +44(0) 1223 496191
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

PolyTherics Ltd
The London Bioscience Innovation Centre
2 Royal College Street
London NW1 0NH
United Kingdom

Telephone: +44 (0)20 7691 4927
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Composite Proteins™

Composite Protein™ technology uses EpiScreen™ technology to map helper CD4+ T cell epitopes within the sequence of the starting protein. T cell epitopes are then removed from the protein as follows;

  • mutations are designed using iTope™ and TCED™ in silico technologies in order to reduce/eliminate binding to human MHC class II
  • T cell receptor contact residues are targeted to disrupt recognition of peptide/MHC class II complexes
  • T cell epitopes are modified to introduce germ-line sequences from related proteins (if available) with high abundance in vivo to which the human immune system is tolerant (e.g. germ-line antibody variable region sequences)
  • structural and homology analysis will guide the targeting and substitution of key amino acids in order to maintain desired protein activity
  • T cell epitopes are prioritized for removal based on potency, and a matrix of sequence variants are designed and tested for the removal of T cell epitopes, whilst avoiding loss of protein activity.